89Bio Inc dividends
ETNB dividends
Ex-dividend | Amount | Yield | Pay date | ||||
---|---|---|---|---|---|---|---|
This company doesn't provide dividends. |
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate is BIO89-100, which is being developed for the treatment of NASH. Currently in a proof of concept Phase 1b/2a clinical trial, BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Learning section - What Is a Dividend?
A dividend is the distribution of reward from a portion of the company's earnings and is paid to a class of its shareholders. Dividends are decided and managed by the company's board of directors, though they must be approved by the shareholders through their voting rights